These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 17568948

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Antigenicity and immunogenicity of a novel chimeric peptide antigen based on the P. vivax circumsporozoite protein.
    Céspedes N, Arévalo-Herrera M, Felger I, Reed S, Kajava AV, Corradin G, Herrera S.
    Vaccine; 2013 Oct 01; 31(42):4923-30. PubMed ID: 23954378
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys.
    Arévalo-Herrera M, Castellanos A, Yazdani SS, Shakri AR, Chitnis CE, Dominik R, Herrera S.
    Am J Trop Med Hyg; 2005 Nov 01; 73(5 Suppl):25-31. PubMed ID: 16291763
    [Abstract] [Full Text] [Related]

  • 7. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit.
    Valderrama-Aguirre A, Quintero G, Gómez A, Castellanos A, Pérez Y, Méndez F, Arévalo-Herrera M, Herrera S.
    Am J Trop Med Hyg; 2005 Nov 01; 73(5 Suppl):16-24. PubMed ID: 16291762
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
    Devi YS, Mukherjee P, Yazdani SS, Shakri AR, Mazumdar S, Pandey S, Chitnis CE, Chauhan VS.
    Vaccine; 2007 Jul 09; 25(28):5166-74. PubMed ID: 17544179
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.
    Bouillet LÉ, Dias MO, Dorigo NA, Moura AD, Russell B, Nosten F, Renia L, Braga EM, Gazzinelli RT, Rodrigues MM, Soares IS, Bruna-Romero O.
    Infect Immun; 2011 Sep 09; 79(9):3642-52. PubMed ID: 21730090
    [Abstract] [Full Text] [Related]

  • 16. Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors.
    Atcheson E, Bauza K, Salman AM, Alves E, Blight J, Viveros-Sandoval ME, Janse CJ, Khan SM, Hill AVS, Reyes-Sandoval A.
    Infect Immun; 2018 Sep 09; 86(9):. PubMed ID: 29986894
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites.
    Bauza K, Malinauskas T, Pfander C, Anar B, Jones EY, Billker O, Hill AV, Reyes-Sandoval A.
    Infect Immun; 2014 Mar 09; 82(3):1277-86. PubMed ID: 24379295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.